TR200102002T2 - The matrix tablet that releases gliclazide in a long time after oral administration. - Google Patents

The matrix tablet that releases gliclazide in a long time after oral administration.

Info

Publication number
TR200102002T2
TR200102002T2 TR2001/02002T TR200102002T TR200102002T2 TR 200102002 T2 TR200102002 T2 TR 200102002T2 TR 2001/02002 T TR2001/02002 T TR 2001/02002T TR 200102002 T TR200102002 T TR 200102002T TR 200102002 T2 TR200102002 T2 TR 200102002T2
Authority
TR
Turkey
Prior art keywords
gliclazide
releases
matrix tablet
long time
oral administration
Prior art date
Application number
TR2001/02002T
Other languages
Turkish (tr)
Inventor
Huet De Barochez Bruno
Wuthrich Partick
Martin Louis
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9541429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200102002(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of TR200102002T2 publication Critical patent/TR200102002T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Mevcut bulus, gliklazid'in uzun sürede salinmasini saglayan matris tablete iliskin olup, özelligi en azindan bir selüloz polimer bilesigi ile bir glikoz surubu kombinasyonunu içermesi, söz konusu kombinasyonun gliklazid'in uzun sürede salinmasinin kontrolünü saglamasi ve gliklazid çözünme kinetiginin pH degisikliklerine karsi duyarsiz olmasini saglamasidir.The present invention relates to the matrix tablet that provides long-term release of gliclazide, which includes a combination of at least one combination of a cellulose polymer compound with a glucose slurry, that the combination provides a control of the release of the gliclazide over a long period of time and is insensitive to pH changes of the glycidide dissolution kinetics. .

TR2001/02002T 1999-02-01 1999-10-15 The matrix tablet that releases gliclazide in a long time after oral administration. TR200102002T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9901082A FR2788981B1 (en) 1999-02-01 1999-02-01 MATRIX TABLET FOR THE EXTENDED RELEASE OF GLICLAZIDE AFTER ORAL ADMINISTRATION

Publications (1)

Publication Number Publication Date
TR200102002T2 true TR200102002T2 (en) 2002-01-21

Family

ID=9541429

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02002T TR200102002T2 (en) 1999-02-01 1999-10-15 The matrix tablet that releases gliclazide in a long time after oral administration.

Country Status (37)

Country Link
US (1) US6733782B1 (en)
EP (1) EP1148871B1 (en)
JP (2) JP4716465B2 (en)
KR (1) KR100491600B1 (en)
CN (1) CN1160061C (en)
AP (1) AP1243A (en)
AT (1) ATE296621T1 (en)
AU (1) AU764516B2 (en)
BR (1) BR9917012A (en)
CA (1) CA2273420C (en)
CZ (1) CZ298196B6 (en)
DE (1) DE69925639T2 (en)
DK (1) DK1148871T3 (en)
EA (1) EA002625B1 (en)
EE (1) EE05024B1 (en)
ES (1) ES2241323T3 (en)
FR (1) FR2788981B1 (en)
GE (1) GEP20053501B (en)
HK (1) HK1043049A1 (en)
HR (1) HRP20010632B1 (en)
HU (1) HU225693B1 (en)
ID (1) ID30225A (en)
IL (2) IL144246A0 (en)
ME (1) ME00436B (en)
NO (1) NO329951B1 (en)
NZ (1) NZ512878A (en)
OA (1) OA11756A (en)
PL (1) PL194505B1 (en)
PT (1) PT1148871E (en)
RS (1) RS50121B (en)
SA (1) SA00210446B1 (en)
SK (1) SK285209B6 (en)
TR (1) TR200102002T2 (en)
UA (1) UA68414C2 (en)
WO (1) WO2000018373A1 (en)
YU (1) YU53101A (en)
ZA (1) ZA200106305B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
SE0200539D0 (en) * 2002-02-25 2002-02-25 Metcon Medicin Ab Granulation process and starch granulate
CN100391459C (en) * 2003-05-26 2008-06-04 沈阳药科大学 Doxazosin mesilate slow releasing preparation
CN1294908C (en) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 Oral gliclazide sustained release formulation
JP2007534704A (en) * 2004-04-29 2007-11-29 美時化学製薬股▲ふん▼有限公司 Oral sustained release tablet composition and method for producing the same
CN100413491C (en) * 2004-06-14 2008-08-27 北京德众万全药物技术开发有限公司 Sustained release preparation of solution resistant medicine
EP1827453A1 (en) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
WO2007055329A1 (en) * 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation Controlled release solid preparation
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
TR200704897A1 (en) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Glyclazide formulations providing extended release @
TR200708938A2 (en) * 2007-12-26 2008-11-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Glyclazide tablet for extended release
ITFI20080016A1 (en) * 2008-02-05 2009-08-06 Valpharma Sa PHARMACEUTICAL FORMULATIONS ORAL CONTAINING GLYCLAZIDE.
FR2928836B1 (en) * 2008-03-21 2011-08-26 Servier Lab SECURE GALENIC FORM FOR MODIFIED RELEASE OF THE ACTIVE INGREDIENT
WO2009140279A2 (en) * 2008-05-12 2009-11-19 Concert Pharmaceuticals, Inc. Sulfonyl urea compounds
EP2181705A1 (en) 2008-10-31 2010-05-05 Disphar International B.V. Sustained-release formulation of gliclazide
CA2753057C (en) * 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
MX339452B (en) 2010-06-16 2016-05-27 Teijin Pharma Ltd Controlled release nucleated tablet.
EP2468268B1 (en) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Combination composition of vildagliptin and gliclazide
TR201107482A1 (en) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. The bilayer combination composition of vildagliptin and glyclazide.
TR201103946A1 (en) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Glyclazide formulations for controlled release.
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
IN2014DN07897A (en) 2012-02-24 2015-04-24 Ranbaxy Lab Ltd
WO2014128116A1 (en) 2013-02-19 2014-08-28 Sanovel Ilac Sanayi Ve Ticaret A.S. A production process for gliclazide formulations
ITFI20130184A1 (en) 2013-08-01 2015-02-02 Valpharma Internat S P A PHARMACEUTICAL FORMULATION OF GLYCLAZIDE WITH MODIFIED RELEASE, ADMINISTRABLE BY ORAL ROUTE, AND ITS PRODUCTION METHOD.
ITMI20132065A1 (en) * 2013-12-11 2015-06-12 Farmatron Ltd THERAPEUTIC RELEASE SYSTEMS MODIFIED FOR ORAL CURCUMIN ADMINISTRATION IN THE TREATMENT OF INTESTINAL DISEASES
LT3170005T (en) 2014-07-18 2019-07-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
WO2016042568A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of gliclazide
CN111329841B (en) * 2020-03-04 2021-11-19 山东鲁抗医药集团赛特有限责任公司 Gliclazide sustained release tablet and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US4056623A (en) * 1975-03-05 1977-11-01 Science Union Et Cie, Societe Francaise De Recherche Medicale Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1246188B (en) * 1990-07-27 1994-11-16 Resa Farma PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS HAVING INCREASED SPEED OF DISSOLUTION OF THE ACTIVE SUBSTANCE AND COMPOSITIONS OBTAINED.
DE4336159A1 (en) * 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Highly effective forms of preparation of sulfonylureas that release the active ingredient quickly or in a controlled manner and processes for their preparation
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.

Also Published As

Publication number Publication date
SA00210446B1 (en) 2006-10-11
HRP20010632B1 (en) 2006-02-28
FR2788981B1 (en) 2002-05-17
AP1243A (en) 2004-02-02
EE05024B1 (en) 2008-06-16
PL194505B1 (en) 2007-06-29
PT1148871E (en) 2005-08-31
PL356707A1 (en) 2004-06-28
BR9917012A (en) 2002-04-16
DE69925639D1 (en) 2005-07-07
AP2001002212A0 (en) 2001-09-30
ME00436B (en) 2011-10-10
HRP20010632A2 (en) 2005-02-28
GEP20053501B (en) 2005-05-10
IL144246A0 (en) 2002-05-23
HUP0105365A3 (en) 2002-11-28
SK10952001A3 (en) 2001-12-03
AU764516B2 (en) 2003-08-21
HU225693B1 (en) 2007-06-28
US6733782B1 (en) 2004-05-11
WO2000018373A1 (en) 2000-04-06
DK1148871T3 (en) 2005-09-19
OA11756A (en) 2005-07-19
KR20010093307A (en) 2001-10-27
CN1160061C (en) 2004-08-04
NO20013757L (en) 2001-08-09
NO20013757D0 (en) 2001-07-31
CN1342068A (en) 2002-03-27
NZ512878A (en) 2002-05-31
NO329951B1 (en) 2011-01-31
SK285209B6 (en) 2006-08-03
ZA200106305B (en) 2002-07-31
RS50121B (en) 2009-03-25
JP2008179649A (en) 2008-08-07
CZ298196B6 (en) 2007-07-18
JP2002525310A (en) 2002-08-13
CZ20012661A3 (en) 2001-11-14
EA002625B1 (en) 2002-06-27
CA2273420A1 (en) 2000-08-01
JP4716465B2 (en) 2011-07-06
HK1043049A1 (en) 2002-09-06
CA2273420C (en) 2002-07-09
DE69925639T2 (en) 2006-04-27
EP1148871A1 (en) 2001-10-31
YU53101A (en) 2004-05-12
IL144246A (en) 2006-12-10
ATE296621T1 (en) 2005-06-15
KR100491600B1 (en) 2005-05-27
AU6098299A (en) 2000-04-17
EA200100827A1 (en) 2002-02-28
ID30225A (en) 2001-11-15
EP1148871B1 (en) 2005-06-01
FR2788981A1 (en) 2000-08-04
UA68414C2 (en) 2004-08-16
EE200100398A (en) 2002-10-15
HUP0105365A2 (en) 2002-04-29
ES2241323T3 (en) 2005-10-16

Similar Documents

Publication Publication Date Title
TR200102002T2 (en) The matrix tablet that releases gliclazide in a long time after oral administration.
TR200200966T1 (en) New pharmaceutical compositions and preparation processes of tubercular drugs
NO20001042D0 (en) Ophthalmic delayed release preparations containing water-soluble drugs
EA200500079A1 (en) THE COMPOSITION OF THE TABLET PRAMIPEXOL Slow Delayed
TR199800743A2 (en) Sustained release polymer blend matrix for pharmaceutical application.
BR9913553A (en) Ranolazine sustained release formulation
ATE232091T1 (en) ORAL PHARMACEUTICAL COMPOSITIONS SUSTAINED RELEASE REVERSIBLE PROTON PUMP INHIBITORS
DK0810857T3 (en) Colonic drug delivery composition
TWI235068B (en) Sustained-release pharmaceutical composition
IL106693A (en) Controlled sustained release tablets containing bupropion hydrochloride
TR200101353A2 (en) The use of albumin stabilized paclitaxel in the preparation of a drug for the treatment of solid tumors and the drug obtained
TR199902608T2 (en) Bo�az yumu�at�c� bile�imler.
BR9916974A (en) Detergent tablet
NO20005394D0 (en) Drug delivery compositions consisting of adhesive microspheres
CY1108587T1 (en) PHARMACEUTICAL COMPOSITION FOR MODIFIED LIBERTY OF AN INSULIN AND METFORMIN SENSITIVE
ES2178876T3 (en) FAST DISINTEGRATION PADS.
SE9202250D0 (en) CONTROLLED RELEASE MORPHINE PREPARATION
DE60038536D1 (en) MATRIX SYSTEM WITH DELAYED RELEASE FOR HIGHLY SOLUBLE ACTIVE SUBSTANCES
ATE220898T1 (en) LONG-LASTING RELEASE NIFEDIPINE PREPARATION
ATE306254T1 (en) PREPARATIONS WITH IMPROVED CONTROLLED RELEASE
PT1318792E (en) PROLONGED LIBERATION COMPOSITION CONTAINING CLARITHROMYCIN
EA200001201A3 (en) Matrix tablet for prolonged release of trimetazidine
TR200400187T2 (en) New oral formulation.
TR200402419T4 (en) Oxcarbazepine-containing suspension.
TR200503846T2 (en) Alternative use for modified release insulin sensitiser and use